lamotrigine and Peripheral Nerve Diseases studies

Research Excerpts

Excerpt	Relevance	Reference
"The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain."	7.74	A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007)
"Some opioid-resistant pain conditions can be alleviated by voltage-dependent Na(+) channel blockers such as lamotrigine."	7.71	Non-opioid actions of lamotrigine within the rat dorsal horn after inflammation and neuropathic nerve damage. ( Blackburn-Munro, G; Dickinson, T; Fleetwood-Walker, SM, 2001)
" Multiple multicentre randomised controlled trials have shown clear efficacy of gabapentin and pregabalin for postherpetic neuralgia and painful diabetic neuropathy."	4.84	Antiepileptic drugs in the treatment of neuropathic pain. ( Eisenberg, E; Krivoy, N; River, Y; Shifrin, A, 2007)
"The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain."	3.74	A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007)
"Some opioid-resistant pain conditions can be alleviated by voltage-dependent Na(+) channel blockers such as lamotrigine."	3.71	Non-opioid actions of lamotrigine within the rat dorsal horn after inflammation and neuropathic nerve damage. ( Blackburn-Munro, G; Dickinson, T; Fleetwood-Walker, SM, 2001)
"Lamotrigine is an antiepileptic drug that stabilizes neural membranes by blocking the activation of voltage-sensitive sodium channels and inhibiting the presynaptic release of glutamate."	2.43	Lamotrigine for neuropathic pain. ( Eisenberg, E; Krivoy, N; Shifrin, A, 2005)

Research

Studies (12)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Change in Average Daily Pain Score as Measured Using a Pain Intensity Rating (NRS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (8.33)	18.2507
2000's	11 (91.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Yang, J	1
Gharagozloo, P	1
Yao, J	1
Ilyin, VI	2
Carter, RB	2
Nguyen, P	2
Robledo, S	2
Woodward, RM	1
Hogenkamp, DJ	1
Shao, B	1
Victory, S	1
Goehring, RR	1
Sun, Q	1
Hogenkamp, D	1
Hodges, DD	1
Islam, K	1
Sha, D	1
Zhang, C	1
Sakellaropoulos, G	1
Yogeeswari, P	1
Ragavendran, JV	1
Sriram, D	1
Nageswari, Y	1
Kavya, R	1
Sreevatsan, N	1
Vanitha, K	1
Stables, J	1
Sindrup, SH	1
Keswani, SC	1
Pardo, CA	1
Cherry, CL	1
Hoke, A	1
McArthur, JC	1
Lindia, JA	1
Köhler, MG	1
Martin, WJ	1
Abbadie, C	1
Eisenberg, E	2
Shifrin, A	2
Krivoy, N	2
Coderre, TJ	1
Kumar, N	1
Lefebvre, CD	1
Yu, JS	1
River, Y	1
Rao, RD	1
Flynn, PJ	1
Sloan, JA	1
Wong, GY	1
Novotny, P	1
Johnson, DB	1
Gross, HM	1
Renno, SI	1
Nashawaty, M	1
Loprinzi, CL	1
Carrieri, PB	1
Bonuso, S	1
Bruno, R	1
Vincitorio, CM	1
Caruso, G	1
Blackburn-Munro, G	1
Dickinson, T	1
Fleetwood-Walker, SM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Efficacy of Lamotrigine in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double Blind, Placebo-Controlled Trial[NCT00068445]	Phase 3	131 participants (Actual)	Interventional	2004-02-29	Completed
The Kinetics of Endocannabinoids in Patients With Chemotherapy Induced Peripheral Neuropathy by Using a Portable Metered-Dose Cannabis Inhaler[NCT04376437]		40 participants (Anticipated)	Interventional	2022-03-15	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change in mean score for average daily pain from baseline to week 10 using the Pain Intensity Rating (NRS) are reported below. The NRS scale ranges from 0 to 10 with higher scores corresponding to having more pain. (NCT00068445)
Timeframe: From baseline to week 10

Change in Average Pain Score as Measured Using the European Cooperative Oncology Group (ECOG) Neuropathy Scale (ENS)

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	-0.3
Arm II - Placebo	-0.5

The change in mean score for average daily pain from baseline to week 10 using the European Cooperative Oncology Group (ECOG) neuropathy scale (ENS) are reported below. The ENS scale goes from 0 to 3 with 0=none, 1=mild paresthesias, 2=mild or moderate sensory loss and/or moderate paresthesias, and 3=severe sensory loss or paresthesias that interfere with function. (NCT00068445)
Timeframe: From baseline to week 10

Change in Brief Pain Inventory (BPI) Average Pain Score [Week 10 Minus Baseline]

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	-0.4
Arm II - Placebo	-0.3

The average change in Brief Pain Inventory (BPI) Average Pain scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine. (NCT00068445)
Timeframe: From baseline to week 10

Change in Brief Pain Inventory (BPI) Least Pain Score [Week 10 Minus Baseline]

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	-0.1
Arm II - Placebo	-0.8

"The average change in Brief Pain Inventory (BPI) Least Pain scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.~Time Frame:~Up to 1 week post-treatment" (NCT00068445)
Timeframe: From baseline to week 10

Change in Brief Pain Inventory (BPI) Pain Interference Score [Week 10 Minus Baseline]

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	0.2
Arm II - Placebo	0.1

The average change in Brief Pain Inventory (BPI) Pain Interference scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine. (NCT00068445)
Timeframe: From baseline to week 10

Change in Brief Pain Inventory (BPI) Pain Now Score [Week 10 Minus Baseline]

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	-0.5
Arm II - Placebo	-0.8

The average change in Brief Pain Inventory (BPI) Pain Now scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine. (NCT00068445)
Timeframe: From baseline to week 10

Change in Brief Pain Inventory (BPI) Pain Relief Score [Week 10 Minus Baseline]

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	-0.1
Arm II - Placebo	-0.3

The average change in Brief Pain Inventory (BPI) Pain Relief scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine. (NCT00068445)
Timeframe: From baseline to week 10

Change in Brief Pain Inventory (BPI) Worst Pain Score [Week 10 Minus Baseline]

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	6.7
Arm II - Placebo	0.4

The average change in Brief Pain Inventory (BPI) Worst Pain scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine. (NCT00068445)
Timeframe: From baseline to week 10

Change in POMS Total Score [Week 10 Minus Baseline]

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	0.1
Arm II - Placebo	-0.6

The average change in POMS Total scores between baseline and week 10 using Wilcoxon test are reported for each arm below. The POMS scales are calculated from patient responses on 30 questions asking how they have been feeling during the past week. The scores are all transformed so that 0 is the worst possible value and 100 is the best possible value. (NCT00068445)
Timeframe: From baseline to week 10

The Change in Overall Quality of Life as Measured by the Uniscale QOL From Baseline to Week 10

Intervention	units on a scale (Mean)
Arm I - Lamotrigine	1.4
Arm II - Placebo	1.3

The change in overall quality of life as measured by the Uniscale QOL (Week 10 minus Baseline) using the Wilcoxon test is reported for each arm below. The Uniscale is a score that ranges from 0 to 100, with 0 being QOL as bad as it can be and 100 being as good as it can be. (NCT00068445)
Timeframe: From baseline to week 10

Article	Year
HIV-associated sensory neuropathies. AIDS (London, England), 2002, Nov-08, Volume: 16, Issue:16 Topics: Analgesics; Anti-HIV Agents; HIV Infections; Humans; Lamotrigine; Nerve Growth Factors; Pain; Periph	2002
Lamotrigine for neuropathic pain. Expert review of neurotherapeutics, 2005, Volume: 5, Issue:6 Topics: Analgesics; Drug Interactions; Drug Therapy, Combination; Expert Testimony; Female; Humans; Lamotrig	2005
Antiepileptic drugs in the treatment of neuropathic pain. Drugs, 2007, Volume: 67, Issue:9 Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Ami	2007

Article	Year
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 2008, Jun-15, Volume: 112, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Evaluation; Female;	2008
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 2008, Jun-15, Volume: 112, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Evaluation; Female;	2008
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 2008, Jun-15, Volume: 112, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Evaluation; Female;	2008
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 2008, Jun-15, Volume: 112, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Evaluation; Female;	2008

Article	Year
3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. Journal of medicinal chemistry, 2004, Mar-11, Volume: 47, Issue:6 Topics: Analgesics; Animals; Cell Line; Humans; Male; Pain; Patch-Clamp Techniques; Peripheral Nervous Syste	2004
Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors. Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17 Topics: Analgesics; Animals; Animals, Newborn; Brain; Cell Line; Humans; In Vitro Techniques; Male; NAV1.2 V	2004
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach. Journal of medicinal chemistry, 2007, May-17, Volume: 50, Issue:10 Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia;	2007
Nicotinic acetylcholine receptor agonism: progress in the management of neuropathic pain? Pain, 2009, Volume: 146, Issue:3 Topics: Azetidines; Excitatory Amino Acid Antagonists; Humans; Lamotrigine; Nicotinic Agonists; Pain; Periph	2009
Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain, 2005, Volume: 117, Issue:1-2 Topics: Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Gan	2005
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. Journal of neurochemistry, 2007, Volume: 100, Issue:5 Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease	2007
Efficacy of lamotrigine on sensory symptoms and pain in peripheral neuropathies. Journal of pain and symptom management, 1999, Volume: 18, Issue:3 Topics: Aged; Anticonvulsants; Female; Humans; Lamotrigine; Male; Middle Aged; Pain; Peripheral Nervous Syst	1999
Non-opioid actions of lamotrigine within the rat dorsal horn after inflammation and neuropathic nerve damage. Neuroscience research, 2001, Volume: 39, Issue:4 Topics: Action Potentials; Analgesics, Opioid; Animals; Anti-Anxiety Agents; Calcium Channel Blockers; Chole	2001

lamotrigine and Peripheral Nerve Diseases